Dosing — 2026-05-07
Tesamorelin is one of the most well-characterized GHRH analogs in the research literature. Unlike newer compounds where dosing is still being refined, tesamorelin has Phase 3 data from the EGRIFTA program defining what works — and where the limits of efficacy show up. This article summarizes the dosing landscape and the evidence around cycling, timing, and protocol length.
Quick note for researchers sourcing material: code WELCOME unlocks 35% off Tesamorelin 10mg vials and our Metabolic, Shredder, and Shred & Bulk stacks at checkout. If you're running a 26-week visceral-fat reduction study, getting purity right at the start saves you from re-running a 6-month protocol on questionable material.
The Phase 3 trials (Falutz et al., NEJM 2007; Stanley et al., JAMA 2014) all used 2 mg subcutaneous daily. This is the dose that produced the headline outcomes: - ~15-18% reduction in visceral adipose tissue (VAT) at 26 weeks - Modest but real improvements in triglycerides - IGF-1 elevation into the upper-normal range - Lean mass preservation across the trial period
There is no published trial data establishing a higher dose as more effective. Some research protocols explore 1 mg daily for tolerability or cost reasons; the data suggest it is roughly half as effective on VAT endpoints, with the response curve approximately linear in this range.
Tesamorelin has a short half-life (~26 minutes) and is cleared rapidly. The therapeutic effect is mediated by pulsatile GH release following each injection, with downstream IGF-1 elevation building up over weeks of daily dosing.
This is fundamentally different from how sema, triz, or reta work. Those are designed for steady-state exposure. Tesamorelin works the opposite way — each injection produces a discrete GH pulse that mimics natural physiology. Spacing injections out (every other day, twice a week, weekly) does not produce the same downstream IGF-1 response, and trial outcomes do not replicate.
If a researcher wants weekly administration on the GH axis, CJC-1295 with DAC is the tool — not tesamorelin.
The pivotal trials did not standardize injection time, but a few patterns have emerged in subsequent research:
A 10 mg vial reconstituted with 2 mL bacteriostatic water gives 5 mg/mL. At that concentration:
A single 10 mg vial covers approximately 5 days at 2 mg/day, so most research protocols use 2-3 vials per week of subject coverage. Most stacks (the Shredder Stack, Shred & Bulk Stack) include 1-3 tesa vials per cycle for this reason.
The Phase 3 trials ran 26 weeks. The published extensions ran 52 weeks. Practical patterns:
Cycling tesamorelin (e.g., 12 weeks on, 4 weeks off) is common in research protocols, even though the pivotal trials used continuous administration. Several rationales appear in the literature:
There is no head-to-head trial data showing that cycled administration produces equivalent VAT outcomes to continuous administration. The reasonable interpretation: cycled protocols probably produce slightly less total VAT change than equivalent continuous-dose-weeks, but allow for safer long-term observation.
Tesamorelin is frequently combined with reta and MOTS-C in recomp research (the Shredder Stack). The mechanistic logic is straightforward: - Reta drives the energy deficit (appetite suppression + glucagon-mediated thermogenesis) - Tesamorelin preserves and augments lean mass via GH/IGF-1 - MOTS-C enhances mitochondrial fat oxidation
When tesamorelin is stacked, the 2 mg daily dose stays the same — there is no published data supporting a reduced tesa dose just because other compounds are present. The compounds work on different axes and don't crowd each other.
Phase 3 data identified the consistent tesamorelin side-effect profile: - Injection site reactions (most common, mild) - Arthralgia / fluid retention — GH-mediated, dose-dependent - Mild hyperglycemia — particularly in subjects with pre-existing insulin resistance - IGF-1 elevation — usually monitored to stay within upper-normal range - Carpal tunnel-like symptoms — rare, usually resolves on dose reduction
Glucose monitoring is the practical endpoint to watch most closely, especially if tesamorelin is being stacked with anything that further perturbs metabolic markers.
Tesamorelin dosing is settled science: 2 mg subcutaneous daily, for 12-26 weeks. The data supporting this is robust; deviations from it are mostly about cost, convenience, or stacking decisions, not efficacy. The protocol has remained essentially unchanged since the original EGRIFTA Phase 3 program.
When you're ready to source vials for a 12- or 26-week protocol, code WELCOME gets you 35% off Tesamorelin 10mg, the Metabolic Stack, and the Shredder Stack — every vial ships with a COA showing 99%+ purity and US-based handling.
Disclaimer: All information presented in this article is for educational and informational purposes only. Platinum Biolabs does not promote or endorse the use of peptides for human consumption. All products sold by Platinum Biolabs are intended strictly for laboratory and research use only. Consult a qualified healthcare professional before making any health-related decisions.